Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Netherlands
  4. Euronext Amsterdam
  5. Galapagos NV
  6. Company
    GLPG   BE0003818359

GALAPAGOS NV

(GLPG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Galapagos NV
Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is focused on the discovery and development of small molecule medicines with novel modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company aims to develop a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. In addition, the CompanyÔÇÖs mission is to develop a number of medicines based on the discovery of novel targets. Galapagos NV also discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. Galapagos aims to develop small molecules that inhibit these targets, restore the balance and thereby positively influence the course of the disease.

Number of employees : 1 304 people.
Sales per Business
2020
EUR (in Million)%
Upfront Payments and License Fees411.4286.1%
Milestone46.269.7%
Royalties16.233.4%
Reimbursement Income4.070.9%
Other0.0700%
Goods0.0020%
Other Commercial0.0020%
Sales per region
2020
EUR (in Million)%
United States472.4598.8%
Europe5.611.2%
Managers
NameAgeSinceTitle
Onno van de Stolpe602020Chief Executive Officer
Bart Filius502021President & Chief Operating Officer
Piet Wigerinck552012Chief Scientific Officer
Walid Abi-Saab-2017Chief Medical Officer
Howard Mitchell Rowe, Dr.502010Independent Non-Executive Director
Katrine S. Bosley512013Independent Non-Executive Director
Mary Kerr, Dr.592016Independent Non-Executive Director
Peter Guenter582019Independent Director
Lena Elisabeth Svanberg, Dr.592020Independent Non-Executive Director
Elizabeth Goodwin--VP-Corporate Communications & Investor Relations
Members of the board
NameAgeSinceTitle
Raj Parekh592004Chairman
Howard Mitchell Rowe, Dr.502010Independent Non-Executive Director
Katrine S. Bosley512013Independent Non-Executive Director
Mary Kerr, Dr.592016Independent Non-Executive Director
Peter Guenter582019Independent Director
Linda Slanec Higgins, Dr.572019Director
Daniel O'Day562019Director
Lena Elisabeth Svanberg, Dr.592020Independent Non-Executive Director
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 65,511,581 48,338,067 73.8% 0 0.0% 73.8%
Shareholders
NameEquities%
Gilead Sciences, Inc. 16,707,477 25.5%
Van Herk Investments BV 4,893,235 7.47%
Capital Research & Management Co. (International Investors) 2,923,555 4.46%
Wellington Management Co. LLP 2,752,374 4.20%
Norges Bank Investment Management 1,231,622 1.88%
The Vanguard Group, Inc. 1,171,833 1.79%
Capital Research & Management Co. (Global Investors) 1,137,932 1.74%
Lyxor International Asset Management SAS 1,062,885 1.62%
Capital Research & Management Co. (World Investors) 933,678 1.43%
BlackRock Fund Advisors 841,738 1.28%
Company contact information
Galapagos NV
Industriepark Mechelen Noord
Generaal de Wittelaan L11 A3
Mechelen, Brussels Region 2800

Phone : +32.1.534.29.00
Fax : +32.1.534.29.01
Web : http://www.glpg.com
Sector Other Biotechnology & Medical Research
1st jan.Capitalization (M$)
GALAPAGOS NV-21.60%4 902
MODERNA, INC.90.67%79 980
LONZA GROUP LTD14.63%52 508
IQVIA HOLDINGS INC.33.76%45 934
CELLTRION, INC.-24.79%32 465
SEAGEN INC.-10.75%28 367
HANGZHOU TIGERMED CONSULTING CO., LTD14.49%24 102
PHARMARON BEIJING CO., LTD.62.65%23 432
CUREVAC N.V.-23.60%21 497
ALNYLAM PHARMACEUTICALS, INC.36.10%20 793
INCYTE CORPORATION-4.43%18 465
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.43.19%17 774
BIO-TECHNE CORPORATION36.01%16 797
PPD, INC.35.36%16 288
NOVAVAX, INC.56.24%12 918
ICON PUBLIC LIMITED COMPANY8.82%11 215
PRA HEALTH SCIENCES, INC.33.28%10 833
QIAGEN N.V.-10.84%10 763
CRISPR THERAPEUTICS AG-16.51%10 242
GENSCRIPT BIOTECH CORPORATION191.22%8 779
SYNEOS HEALTH, INC.23.94%8 746